Rapid point-of-care testing for sexually transmitted infections, offering results within a clinic visit rather than requiring send-out laboratory testing with results returning days later, continues expanding across clinics, urgent care, and sexual health-focused care settings — a shift with meaningful public health value given how much same-visit treatment can improve both individual outcomes and transmission reduction.
The Public Health Case for Same-Visit Testing
Traditional send-out STI testing creates a real gap between testing and treatment, during which a patient may not return for results or may continue transmission risk behavior unaware of their status. Rapid point-of-care testing that supports same-visit diagnosis and treatment initiation closes that gap meaningfully, a benefit increasingly recognized by both clinical guidelines and public health funding priorities.
What Clinics Adopting This Need
- CLIA waiver compliance for the specific point-of-care platforms used, ensuring the testing complexity level matches the clinic's laboratory certification status
- Adequate test kit inventory management matched to actual patient volume, avoiding both stockouts that undermine the same-visit value proposition and excess inventory carrying cost for testing categories with defined shelf life
- Staff training on both correct testing technique and the sensitive patient communication needed when delivering same-visit results, a different clinical conversation dynamic than results delivered after a delay
Where Adoption Is Concentrated
Adoption has concentrated most heavily at dedicated sexual health clinics and urgent care sites in higher-prevalence areas, though broader primary care adoption continues growing as point-of-care platform costs decline and clinical guidelines increasingly recommend routine testing access.
Clinics building point-of-care testing programs can review Healix Medical Supply's diagnostic equipment catalog.
